BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36934612)

  • 1. L-asparaginase immobilization in supramolecular nanogels of PEG-grafted poly HPMA and bis(α-cyclodextrin) to enhance pharmacokinetics and lower enzyme antigenicity.
    Monajati M; Tamaddon AM; Abolmaali SS; Yousefi G; Javanmardi S; Borandeh S; Heidari R; Azarpira N; Dinarvand R
    Colloids Surf B Biointerfaces; 2023 May; 225():113234. PubMed ID: 36934612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo.
    Jean-François J; D'Urso EM; Fortier G
    Biotechnol Appl Biochem; 1997 Dec; 26(3):203-12. PubMed ID: 9428158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
    Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
    Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
    Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
    Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.
    Yamada T; Ishimaru M; Shoji T; Tomiyasu H; Tochinai R; Taguchi K; Komatsu T
    ACS Appl Bio Mater; 2023 Dec; 6(12):5789-5797. PubMed ID: 38047730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
    Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
    Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid-phase enzyme modification via affinity chromatography.
    Baran ET; Ozer N; Hasirci V
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Sep; 794(2):311-22. PubMed ID: 12954382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and toxicity of intramuscular 1000 iu/m
    Sidhu J; Masurekar AN; Gogoi MP; Fong C; Ioannou T; Lodhi T; Parker C; Liu J; Kirkwood AA; Moorman AV; Das K; Goulden NJ; Vora A; Saha V; Krishnan S
    Br J Haematol; 2022 Jul; 198(1):142-150. PubMed ID: 35348200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Fe
    Ulu A; Noma SAA; Koytepe S; Ates B
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1035-1045. PubMed ID: 29873527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase activities during intensified treatment with pegylated
    Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
    Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetic studies of three asparaginase preparations.
    Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
    J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peg-Grafted Liposomes for L-Asparaginase Encapsulation.
    de Souza Guimarães M; Cachumba JJM; Bueno CZ; Torres-Obreque KM; Lara GVR; Monteiro G; Barbosa LRS; Pessoa A; Rangel-Yagui CO
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
    Nandy P; Periclou AP; Avramis VI
    Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
    Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel site-specific PEGylated L-asparaginase.
    Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of native Escherichia coli asparaginase.
    Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
    Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
    Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior operational stability of immobilized L-asparaginase over surface-modified carbon nanotubes.
    Almeida MR; Cristóvão RO; Barros MA; Nunes JCF; Boaventura RAR; Loureiro JM; Faria JL; Neves MC; Freire MG; Santos-Ebinuma VC; Tavares APM; Silva CG
    Sci Rep; 2021 Nov; 11(1):21529. PubMed ID: 34728685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.